Jones D B, Howden C W, Burget D W, Kerr G D, Hunt R H
Division of Gastroenterology Unit, McMaster University, Hamilton, Ontario, Canada.
Gut. 1987 Sep;28(9):1120-7. doi: 10.1136/gut.28.9.1120.
FVMany different dosage schedules of antisecretory drugs for the treatment of duodenal ulcer are recommended. The relationship between degree of acid suppression and therapeutic efficacy has not been precisely defined for these drugs. We have examined the association between suppression of intragastric acidity and duodenal ulcer healing rates for a number of therapeutic regimens. For the H2 receptor antagonists alone, the most significant correlation with healing rates was with suppression of intragastric acidity at night (r = 0.926; p = 0.0001). When other classes of drug: high dose antacid, omeprazole and a synthetic prostaglandin (enprostil) were included in the analysis, the closest correlation was with suppression of total 24 hour intragastric acidity (r = 0.911; p less than F0.0001). Stepwise linear regression analysis was used to investigate the relative contributions to healing of suppression of acidity during the day and night. Suppression of nocturnal acidity was found to be the single most important factor in explaining healing rates. No further benefit was obtained with daytime suppression for H2 receptor antagonists; suppression of acidity at night accounted for 86.1% of the observed variation in healing rates among different regimens of H2 receptor antagonists. When all classes of drugs were analysed, inclusion of daytime suppression produced a significant improvement in correlation over nocturnal suppression alone. Drug regimens providing potent suppression of nocturnal acidity produce the highest healing rates in controlled clinical trials. The healing rate for any dose regimen of an antisecretory drug can be predicted from a knowledge of its effect on intragastric acidity. For the H2 receptor antagonists, suppression of nocturnal acidity is the most relevant in this context. Moderate suppression of acidity achieves ulcer healing rates at four to eight weeks which are comparable with those seen with potent suppression at two to four weeks. Increasing degrees of suppression merely accelerate healing.
治疗十二指肠溃疡的抗分泌药物有许多不同的给药方案。这些药物的抑酸程度与治疗效果之间的关系尚未明确界定。我们研究了多种治疗方案中胃内酸度抑制与十二指肠溃疡愈合率之间的关联。仅对于H2受体拮抗剂,与愈合率最显著的相关性是夜间胃内酸度的抑制(r = 0.926;p = 0.0001)。当分析中纳入其他类药物:高剂量抗酸剂、奥美拉唑和一种合成前列腺素(恩前列素)时,最密切的相关性是24小时总胃内酸度的抑制(r = 0.911;p小于0.0001)。采用逐步线性回归分析来研究白天和夜间酸度抑制对愈合的相对贡献。发现夜间酸度抑制是解释愈合率的唯一最重要因素。对于H2受体拮抗剂,白天抑制没有进一步的益处;夜间酸度抑制占不同H2受体拮抗剂治疗方案中观察到的愈合率变化的86.1%。当分析所有类药物时,纳入白天抑制比仅夜间抑制在相关性上有显著改善。在对照临床试验中,能有效抑制夜间酸度的药物方案产生最高的愈合率。抗分泌药物任何剂量方案的愈合率都可以根据其对胃内酸度的影响来预测。对于H2受体拮抗剂,在这种情况下夜间酸度抑制最为相关。适度的酸度抑制在4至8周时能达到与2至4周强效抑制相当的溃疡愈合率。抑制程度的增加仅仅加速愈合。